NervGen Pharma Corp. (NGEN) — Cash Flow-to-Debt Ratio
NervGen Pharma Corp. (NGEN) has a Cash Flow-to-Debt Ratio of -0.51x as of December 2025, meaning its operating cash flow of $-10.13 Million could theoretically repay -1% of its total liabilities ($19.73 Million) in one year. See NervGen Pharma Corp. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NervGen Pharma Corp. Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for NervGen Pharma Corp. across 8 annual periods. Also explore net asset momentum of NervGen Pharma Corp. to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NervGen Pharma Corp. (2018–2025)
Year-by-year debt coverage analysis for NervGen Pharma Corp.. For market capitalisation and broader financial context, see NervGen Pharma Corp. market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.99x | $-19.50 Million | $19.73 Million | ▲ +0.8% |
| 2024 | -1.00x | $-11.70 Million | $11.75 Million | ▼ -34.4% |
| 2023 | -0.74x | $-8.52 Million | $11.50 Million | ▲ +56.6% |
| 2022 | -1.71x | $-13.12 Million | $7.68 Million | ▲ +77.7% |
| 2021 | -7.67x | $-6.54 Million | $852.33K | ▲ +8.2% |
| 2020 | -8.35x | $-4.95 Million | $592.68K | ▲ +4.7% |
| 2019 | -8.76x | $-6.24 Million | $712.51K | ▼ -391.1% |
| 2018 | -1.78x | $-761.52K | $426.93K | — |